Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:ONC)

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

PR Newswire 8 days ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire May 16, 2024

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

PR Newswire May 15, 2024

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

PR Newswire May 9, 2024

Oncolytics Biotech approved to expand pancreatic cancer program

Trevor Abes  May 9, 2024

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

PR Newswire May 9, 2024

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

PR Newswire May 8, 2024

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire April 30, 2024

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

PR Newswire April 25, 2024
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

RE:RE:Strategic Combinations: Future of OV therapy with reovirus

Does anybody have any idea of how any of the mouse studies on Pelareorep compare to the actual human studies that followed?. Is there a...
m00nsh0ts - 9 hours ago

RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

May 28, 2024 - Daiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca unable to show OS with ADC Enhertu follow-on in...
Noteable - 12 hours ago

RE:RE:RE:RE:Strategic Combinations: Future of OV therapy with reovirus

No, just a guy that hoped to make money. Now I'm just hoping to recoup some loss. 
13X2413 - 16 hours ago

RE:RE:RE:Strategic Combinations: Future of OV therapy with reovirus

13X unstable is a broken AI algorithm out of control! 10B are coming sit tight!
Lesalpes29 - 16 hours ago

RE:RE:RE:Strategic Combinations: Future of OV therapy with reovirus

Are you one of those mining and energy traders who have been sitting on the share price?
Noteable - 1 day ago

RE:RE:Strategic Combinations: Future of OV therapy with reovirus

You're making it sound like it's a good thing that you were educating everyone 2.5 years ago. You do realize that the stock is...
13X2413 - 1 day ago
View more Bullboard ››

Trillion Energy International Inc.

Trillion Energy International Inc.

Trillion Energy International Inc. is a Canada-based oil and gas producing company that strives to maximize shareholder value ...
View More »